The bottom line: A randomized Phase 2b trial found that one infusion of the experimental cell product laromestrocel improved six-minute walking distance in older adults with mild to moderate frailty at nine months. The result is promising human evidence, but it does not establish an approved treatment, reverse aging or answer whether benefits last.
Frailty is more than getting older
Frailty is a clinical syndrome in which the body has less reserve to recover from stress. A minor infection, fall or hospital stay can produce a larger decline than it would in a more resilient person. Common features include weakness, fatigue, slower movement, low activity and unintentional weight loss.
Frailty raises the risk of disability, hospitalization and loss of independence. Exercise, nutrition, medication review and treatment of underlying disease can help, but there is no approved drug that directly treats aging-related frailty as one condition.
What laromestrocel is
Laromestrocel, also known as Lomecel-B, is an investigational product made from mesenchymal stromal cells obtained from the bone marrow of healthy adult donors. These cells are sometimes called mesenchymal stem cells, although their proposed therapeutic role is thought to depend largely on the signals they release rather than their permanently replacing damaged tissue.
The developer, Longeveron, proposes that the cells may affect inflammation, blood-vessel function and tissue repair. Laromestrocel is not approved by the US Food and Drug Administration for frailty.
How the trial worked
The double-blind, placebo-controlled trial enrolled adults ages 70 to 85 with mild or moderate frailty and no dementia. A total of 148 people received a single intravenous infusion and were included in the safety analysis. Participants were assigned to placebo or one of four doses containing 25 million, 50 million, 100 million or 200 million cells.
The primary outcome was the six-minute walk test, a simple measure of how far a person can walk on a flat surface in six minutes. It reflects endurance and mobility, although it can also be influenced by motivation, arthritis, heart and lung function, and familiarity with the test.
Compared with placebo, increasing doses of laromestrocel were associated with larger improvements in walking distance. At nine months, the modeled dose response corresponded to a 63.4-meter improvement, with a 95% confidence interval from 17.1 to 109.6 meters. At six months, the estimated difference was 41.3 meters, but the confidence interval crossed zero and the conventional statistical threshold was not met.
Changes in walking distance correlated with a patient-reported physical-function score. The researchers also reported that higher doses were associated with lower levels of soluble TIE2, a blood marker related to vascular signaling. That biomarker may help generate a mechanism, but its movement is not proof that blood vessels or aging were restored.
What readers should not conclude
The study did not show that participants became biologically younger or lived longer. It evaluated one functional endpoint over nine months in a selected group of ambulatory adults. The trial was designed to identify a dose and a signal, not to provide the definitive evidence expected from a large Phase 3 program.
The dose-response analysis combined information across several relatively small groups. The highest-dose group included fewer participants than the other arms. Seven randomized participants withdrew before infusion and were excluded from the efficacy population, while 143 had at least one follow-up visit.
Important questions remain about durability, repeat dosing, rare adverse effects and which patients might benefit. A later trial should confirm the walking result using a prespecified dose and should measure falls, hospitalizations, disability, daily activity and quality of life. Independent replication would strengthen confidence.
The study also has a commercial connection. Several authors were affiliated with Longeveron, the company developing laromestrocel. That does not invalidate the trial, which used randomization, blinding, placebo control and independent oversight. It does make transparent methods, full reporting and independent confirmation especially important.
The Lifespan Brief verdict
This is more than a cell experiment or an animal study. It is a controlled human trial with a functional primary endpoint, and the nine-month walking result is clinically interesting. That places laromestrocel ahead of many longevity interventions that have only changed biomarkers.
It is still a mid-stage trial of an investigational product. One encouraging outcome does not establish that stem cells treat frailty, and the term stem cell therapy should not be read as tissue rejuvenation. The result justifies a larger confirmatory trial. It does not justify purchasing unapproved cell treatments from clinics that claim to reverse aging.
Sources
- Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty, Cell Stem Cell, 2026.
- ClinicalTrials.gov record NCT03169231.
This article is for general information and is not personal medical advice.